Skip to content
Triangle logo TriangleGet started
← All settings

DISEASE & TREATMENT SETTING

Mast Cell Leukemia

Source-derived catalogue. This is not a treatment recommendation or a personalised trial match.

Exact scope

Mast Cell Leukemia

Source population
Not part of this definition
Disease extent
Not part of this definition
Treatment line
Not part of this definition
Stage
Not part of this definition
Resectability
Not part of this definition
Biomarkers, prior therapy and derivation
molecular
    prior therapy
      derivation status
      source-attested
      derivation note
      Added because the terminology and the registry both attest it: an NCIt neoplasm concept named by 6 acquired study condition(s). It is absent from the NCI treatment-topic directory, which is not an exhaustive cancer inventory.
      source wording
      Source null

      Study evidence for this setting

      6 linked studies · Applicability is a draft source assessment, not a determination of your eligibility.

      NCT00112593 · Registry condition search · Scope: narrower

      Fludarabine and Total-Body Irradiation Followed By Donor Stem Cell Transplant and Cyclosporine and Mycophenolate Mofetil in Treating HIV-Positive Patients With or Without Cancer

      6 outcome links · 1 safety-group records · 0 quality-of-life measures

      →

      NCT00118352 · Registry condition search · Scope: narrower

      Alemtuzumab, Fludarabine Phosphate, and Total-Body Irradiation Followed by Cyclosporine and Mycophenolate Mofetil in Treating Patients Who Are Undergoing Donor Stem Cell Transplant

      6 outcome links · 3 safety-group records · 0 quality-of-life measures

      →

      NCT00387426 · Registry condition search · Scope: narrower

      Sunitinib in Treating Patients With Idiopathic Myelofibrosis

      1 outcome links · 1 safety-group records · 0 quality-of-life measures

      →

      NCT01273766 · Registry condition search · Scope: narrower

      Deferasirox in Treating Iron Overload Caused By Blood Transfusions in Patients With Hematologic Malignancies

      3 outcome links · 3 safety-group records · 0 quality-of-life measures

      →

      NCT01869777 · Registry condition search · Scope: narrower

      Bioelectrical Impedance Measurement for Predicting Treatment Outcome in Patients With Newly Diagnosed Acute Leukemia

      6 outcome links · 1 safety-group records · 0 quality-of-life measures

      →

      NCT03580655 · Source cited / selected · Scope: narrower

      (PATHFINDER) Study to Evaluate Efficacy and Safety of Avapritinib (BLU-285), A Selective KIT Mutation-targeted Tyrosine Kinase Inhibitor, in Patients With Advanced Systemic Mastocy

      6 outcome links · 2 safety-group records · 4 quality-of-life measures

      →
      Source relationships and population-mapping limitations
      bindings
      1. release id
        clinical-indications-draft-1
        disease state id
        ds-mast-cell-leukemia
        binding id
        ncit-C3169
        source collection
        ncit-concept
        source key
        C3169
        source excerpt
        Source null
        match status
        exact
        match note
        Source null
        recorded at
        2026-09-10T00:00:00Z
      mappings

        Download this complete draft source relationship record →

        Preserved source evidence · Not medical advice